Cytomegalovirus infection post kidney transplant: What should we know now
Loading...
Files
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Lebanese Order of Physicians
Abstract
Cytomegalovirus (CMV) remains one of the most important pathogen responsible for the morbidity and mortality of transplantation patients. The impact on recipients depends on the form of CMV infection knowing that 10% to 50% develop symptomatic disease while solid organ involvement if presumed (e.g. CMV nephritis) may have deleterious outcome and requires histopathology testing. Treatment with antivirals IV ganciclovir and valganciclovir is managed according to early diagnostic tools with quantitative nucleic acid testing (QNAT) and antigenemia that will indicate the extent of disease and monitor response to treatment. CMV prevention in particular conditions of high risk patients has proven to be beneficial, resistance to antivirals and CMV vaccines along with novel therapies are thoroughly discussed in this review describing the new perspectives of CMV infection management.
Description
Keywords
Cmv, Diagnosis, Ganciclovir, Resistance, Review, Transplant, Treatment, Algorithms, Cytomegalovirus infections, Drug resistance, viral, Humans, Kidney transplantation, Benzimidavir, Cytomegalovirus vaccine, Leflunomide, Letermovir, Valganciclovir, Antigenemia, Cytomegalovirus infection, Ganciclovir resistant cytomegalovirus infection, Histopathology, Human, Immunoassay, Meta analysis (topic), Nephritis, Nucleic acid analysis, Patient care, Phase 2 clinical trial (topic), Polymerase chain reaction, Postoperative period, Preemptive therapy, Primary cytomegalovirus infection, Primary infection, Prophylaxis, Quantitative nucleic acid testing, Randomized controlled trial (topic), Reactivation disease, Serology, Superinfection, Systematic review (topic), Vaccination, Virus culture, Virus resistance, Adverse effects, Algorithm, Antiviral resistance